Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Периндоприл: доказательная база и возможности применения
Периндоприл: доказательная база и возможности применения
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Периндоприл является ингибитором ангиотензинпревращающего фермента (ИАПФ) с одной из наиболее хорошо представленных доказательных баз. Применение препарата уменьшает сердечно-сосудистый риск у пациентов с артериальной гипертензией, ишемической болезнью сердца, сахарным диабетом, перенесенным инфарктом миокарда и инсультом. Обращает на себя внимание также способность периндоприла выраженно уменьшать гипертрофию левого желудочка.
Ключевые слова: ИАПФ, периндоприл, артериальная гипертензия, ишемическая болезнь сердца, инфаркт миокарда, инсульт, индапамид.
Key words: angiotensin-converting enzyme inhibitor, perindopril, arterial hypertension, coronary heart disease, myocardial infarction, stroke, indapamide.
Ключевые слова: ИАПФ, периндоприл, артериальная гипертензия, ишемическая болезнь сердца, инфаркт миокарда, инсульт, индапамид.
________________________________________________
Key words: angiotensin-converting enzyme inhibitor, perindopril, arterial hypertension, coronary heart disease, myocardial infarction, stroke, indapamide.
Полный текст
Список литературы
1. Недогода С.В. Престариум А в лечении артериальной гипертензии и пациентов высокого риска: почему ему отдается предпочтение? Cons. Med. 2010; 1: 45–9.
2. Терещенко Н. EUROPA открывает новые горизонты применения ингибиторов АПФ. Cons. Med. 2003; 11: 664–8.
3. Ferrari R, Pasanisi G, Notarstefano P et al. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005; 3: 15–29.
4. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–45.
5. Карпов Ю.А. Периндоприл: клиническая эффективность у всех больных с сосудистым заболеванием или высоким его риском через вазопротекцию. Cons. Med. 2009; 1: 51–5.
6. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
7. Asmar R, London G, O'Rourke M et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose peridopril/indapamide combination in hypertensive patients. A comparison with atenolol. Hypertension 2001; 38: 922–6.
8. Asmar RG, Topouchian J, Pannier B et al. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. J Hypertens 2001; 19: 813–8.
9. Карпов Ю.А., Шальнова С.А. Деев А.Д. Результаты клинического этапа национальной программы ПРЕМЬЕРА. Прогресс в кардиологии. 2006; 2: 1–4.
10. Gomma AH, Fox KM on behalf of the EUROPA Investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15: 169–79.
11. Daly CA, Fox KM, Remme WJ et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–78.
12. Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators. PERTINENT – perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17 (1): 83–91.
13. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression (from rhe PERindopril's Prospective Effect on Coronary a Theroslerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159–63.
14. Rodriguez-Granillo GA, Serruys PW, Garcia-Garcia HM et al. Coronary artery remodeling is related to plaque composition. Heart 2006; 92: 388–91.
15. Bots ML, Remme WJ, Luscher TF, Grobbee DE. On behalf of the EUROPA-PERFECT investigators. PERin-dopril-Function of the Endothelium in Coronary artery disease Trial: the PERFECT study-sub study of EUROPA: rationale and Design. Cardiovasc Drugs Ther 2002; 16: 227–36.
16. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–40.
17. Dahlof B. The PICXEL study benefits of a low dose combination on left ventricular hypertrophy reduction. XIV European Meeting on Hypertension, Paris, 2004.
18. Dahlof В, Gosse P, Gueret О et al. THE P.I.C.X.E.L study: benefits of Preterax on LVH reduction. J Hypertens 2004; 22 (Suppl. 2): S410, Abstract S9.
19. PREAMI: perindopril and remodelling in elderly with acute myocardial infarction: study rationale and design. Cardiovasc Drugs Ther 2000; 14 (6): 671–9.
20. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS (Perindopril Protection Against Recurrent Stroke Study). Hypertension 1996; 14 (Suppl.): 41–5.
2. Терещенко Н. EUROPA открывает новые горизонты применения ингибиторов АПФ. Cons. Med. 2003; 11: 664–8.
3. Ferrari R, Pasanisi G, Notarstefano P et al. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005; 3: 15–29.
4. Cleland JG, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–45.
5. Карпов Ю.А. Периндоприл: клиническая эффективность у всех больных с сосудистым заболеванием или высоким его риском через вазопротекцию. Cons. Med. 2009; 1: 51–5.
6. Dahlof B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
7. Asmar R, London G, O'Rourke M et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose peridopril/indapamide combination in hypertensive patients. A comparison with atenolol. Hypertension 2001; 38: 922–6.
8. Asmar RG, Topouchian J, Pannier B et al. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. J Hypertens 2001; 19: 813–8.
9. Карпов Ю.А., Шальнова С.А. Деев А.Д. Результаты клинического этапа национальной программы ПРЕМЬЕРА. Прогресс в кардиологии. 2006; 2: 1–4.
10. Gomma AH, Fox KM on behalf of the EUROPA Investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001; 15: 169–79.
11. Daly CA, Fox KM, Remme WJ et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26: 1369–78.
12. Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators. PERTINENT – perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study. Cardiovasc Drugs Ther 2003; 17 (1): 83–91.
13. Rodriguez-Granillo GA. Long-term effect of Perindopril on coronary atherosclerosis progression (from rhe PERindopril's Prospective Effect on Coronary a Theroslerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159–63.
14. Rodriguez-Granillo GA, Serruys PW, Garcia-Garcia HM et al. Coronary artery remodeling is related to plaque composition. Heart 2006; 92: 388–91.
15. Bots ML, Remme WJ, Luscher TF, Grobbee DE. On behalf of the EUROPA-PERFECT investigators. PERin-dopril-Function of the Endothelium in Coronary artery disease Trial: the PERFECT study-sub study of EUROPA: rationale and Design. Cardiovasc Drugs Ther 2002; 16: 227–36.
16. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829–40.
17. Dahlof B. The PICXEL study benefits of a low dose combination on left ventricular hypertrophy reduction. XIV European Meeting on Hypertension, Paris, 2004.
18. Dahlof В, Gosse P, Gueret О et al. THE P.I.C.X.E.L study: benefits of Preterax on LVH reduction. J Hypertens 2004; 22 (Suppl. 2): S410, Abstract S9.
19. PREAMI: perindopril and remodelling in elderly with acute myocardial infarction: study rationale and design. Cardiovasc Drugs Ther 2000; 14 (6): 671–9.
20. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS (Perindopril Protection Against Recurrent Stroke Study). Hypertension 1996; 14 (Suppl.): 41–5.
Авторы
Д.А.Напалков*, А.В.Жиленко
ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
*dminap@mail.ru
I.M.Sechenov First Moscow State Medical University
*dminap@mail.ru
ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ
*dminap@mail.ru
________________________________________________
I.M.Sechenov First Moscow State Medical University
*dminap@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.